Last reviewed · How we verify
NCT04801615
Characteristics of Patients With Necrotizing Soft Tissue Infections
trial testing Surgery in Necrotizing Soft Tissue Infection in 30 participants. Status unknown.
1 January 2025
Quick facts
| Lead sponsor | Aarhus University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 September 2020 |
| Primary completion | 1 January 2025 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Surgery
Conditions studied
- Necrotizing Soft Tissue Infection — all drugs for Necrotizing Soft Tissue Infection →
Sponsor
Aarhus University Hospital
Who can join
Eligibility, any sex, with Necrotizing Soft Tissue Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the demographic characteristic of patients with necrotizing soft tissue infections.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04801615
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Surgery
Trials testing the same drug.
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07524452 — Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, · Phase 3 · recruiting
- NCT07053033 — Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR Be · Phase 2 · recruiting
- NCT07352007 — Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular · Phase 2 · not yet recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other recruiting trials for Necrotizing Soft Tissue Infection
Currently open trials in the same condition.
- NCT06857708 — The Management of Necrotizing Soft Tissue Infection Wounds With Cytal® Wound Matrix and MicroMatrix® · NA · recruiting
- NCT03482245 — The Role of Circadian Clock Proteins in Innate and Adaptive Immunity · NA · recruiting
- NCT06002607 — Shorter Versus Extended Course of Antibiotic Therapy for Necrotizing Soft Tissue Infections · recruiting
Other Aarhus University Hospital trials
Trials by the same sponsor.
- NCT07432802 — Sublobar Wedge Resection or Stereotactic Radiotherapy Treatment of High-risk Patients With Early-stage Lung Cancer · NA · not yet recruiting
- NCT07499336 — UNDERSTANDING THE T-CELL AND B-CELL RECEPTOR REPERTOIRE IN CHILDREN AND YOUNG ADULTS WITH ANTI-DRUG ANTIBODIES AGAINST P · not yet recruiting
- NCT07454486 — TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cance · not yet recruiting
- NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
- NCT07426250 — Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04801615 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aarhus University Hospital
- Last refreshed: 7 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04801615.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing